Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 30;70(Suppl 1):S3-S11.
doi: 10.33549/physiolres.934779.

Parathyroid Hormone-Related Changes of Bone Structure

Affiliations
Review

Parathyroid Hormone-Related Changes of Bone Structure

M Kužma et al. Physiol Res. .

Abstract

Parathyroid hormone (PTH) increases the release of serum calcium through osteoclasts, which leads to bone resorption. Primary, PTH stimulates osteoblasts leading to increase RANKL (receptor activator for nuclear factor kappa-B ligand) expression and thus differentiation of osteoclasts. In kidneys, PTH increases calcium and decrease phosphate reabsorption. In kidneys, PTH stimulates 1alpha-hydroxylase to synthesize active vitamin D. Primary hyperparathyroidism (PHPT) is characterized by skeletal or renal complications. Nowadays, the classical form of PHPT is less seen and asymptomatic or subclinical (oligo symptomatic) forms are more frequent. Previously, it was thought that cortical bone is preferably affected by PHPT and that predispose bones to fracture at sites with a higher amount of cortical bone. However, an increased risk of vertebral fractures has been found by most of the studies showing that also trabecular bone is affected. Bone Mass measurement (BMD) at all skeletal sites is advised, but another specific tool for fracture assessment is needed. Trabecular bone score (TBS), an indirect measure of trabecular bone, maybe a useful method to estimate fracture risk. TBS is associated with vertebral fractures in PHPT regardless of BMD, age, BMI and gender. Furthermore, there is an association between TBS and high resolution peripheral quantitative computed tomography (HR-pQCT) parameters in the trabecular and cortical compartment. However, studies considering the effect of PHPT treatment on TBS are more conflicting. Secondary hyperparathyroidism caused by vitamin D deficiency was associated with impaired bone microarchitecture in all age categories, as measured by TBS and Hr-pQCT with further improvement after treatment with vitamin D.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

There is no conflict of interest.

Figures

Fig. 1
Fig. 1
Main role of parathormone in kidney.
Fig. 2
Fig. 2
Main role of parathormone in bone.

References

    1. ALWAN A, AL RASSY N, BERRO AJ, RIZKALLAH M, MATTA J, FRENN F, BACHOUR F, SEBAALY A, MAALOUF G, ZOUHAL H, EL HAGE R. Vitamin D and trabecular bone score in a group of young Lebanese adults. J Clin Densitom. 2018;21:453–458. doi: 10.1016/j.jocd.2018.02.002. - DOI - PubMed
    1. BANDEIRA F, CUSANO NE, SILVA BC, CASSIBBA S, ALMEIDA CB, MACHADO VCC, BILEZIKIAN JP. Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metab. 2014;58:553–561. doi: 10.1590/0004-2730000003381. - DOI - PMC - PubMed
    1. BILEZIKIAN JP, BRANDI ML, EASTELL R, SILVERBERG SJ, UDELSMAN R, MARCOCCI C, POTTS JT., Jr Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrin Metab. 2014;99:3561–3569. doi: 10.1210/jc.2014-1413. - DOI - PMC - PubMed
    1. BISLEV LS, LANGAGERGAARD RØDBRO L, ROLIGHED L, SIKJAER T, REJNMARK L. Bone microstructure in response to vitamin d3 supplementation: a randomized placebo-controlled trial. Calcified Tissue Int. 2019;104:160–170. doi: 10.1007/s00223-018-0481-6. - DOI - PubMed
    1. BOUTROY S, HANS D, SORNAY-RENDU E, VILAYPHIOU N, WINZENRIETH R, CHAPURLAT R. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int. 2013;24:77–85. doi: 10.1007/s00198-012-2188-2. - DOI - PubMed

Substances